Cart
sales@molnova.com
AGI-14100
CAS No. 1448346-43-7
AGI-14100( —— )
Catalog No. M34048 CAS No. 1448346-43-7
AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 532 | Get Quote |
|
| 5MG | 787 | Get Quote |
|
| 10MG | 1074 | Get Quote |
|
| 25MG | 1463 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAGI-14100
-
NoteResearch use only, not for human use.
-
Brief DescriptionAGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia.
-
DescriptionAGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
RecptorDehydrogenase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1448346-43-7
-
Formula Weight599.96
-
Molecular FormulaC29H22ClF4N5O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN([C@H](C(NC1CC(F)(F)C1)=O)C2=C(Cl)C=CC=C2)(C(=O)[C@H]3N(C(=O)CC3)C4=CC(C#N)=CC=N4)C5=CC(F)=CC(F)=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
DS-1001b
DS-1001b is an ?inhibitor of ?mutant IDH-1 (Isocitrate Dehydrogenase-1).
-
JC2-11
JC2-11 is an inhibitory compound for inflammation.JC2-11 inhibits the recruitment domain-containing proteins NLRC 4, atypical in melanoma 2 (AIM 2) and atypical (NC) inflammatory vesicles by disrupting reactive oxygen species (ROS) production and caspase-1 activity.
-
ASLAN003
ASLAN003 is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity. It has the potential to be a first-in-class candidate in AML.
